A blood test for leukemia? Genetic changes in the blood can be spotted five years before



[ad_1]

Scientists have found acute myeloid leukemia (AML), an aggressive form of the immune cell, a blood test could detect a person's leukemia risk at least five years before they develop cancer. almost always prefaced by certain genetic changes in the bloodstream.

Currently, physicians would be hard-pressed to prevent the progression of leukemia even if they did not start it because they did not have such treatment.

hard-to-treat cancer, allowing doctors to monitor patients' risks in the same way that polyps and moles can be red flags for colon or skin cancers.

 The findings could be a game-changer for the hard-to-treat blood cancer, doctors to monitor patients 'risks in the same way that polyps can be red flags for colon cancers

 The findings could be a game-changer for the hard-to-treat blood cancer, allowing doctors to monitor patients' In the same way that polyps can be red flags for colon cancers

The findings could be a game-changer for the hard-to-treat blood cancer, allowing doctors to monitor patients' risks in the same way that polyps can be red flags for colon cancers [19659008] 'Acute myeloid leukemia often appears very suddenly in patients, so we are surprised to discover that its origins are detectable more than five years before the disease develops,' said joint first author Dr. Grace Collord from the Wellcome Sanger Institute and University of Cambridge.

'This provides proof-of-principle that it may be possible to develop tests to identify people at a high risk of developing AML.'

Leukemia is cancer of the white blood cells, which are key fighting infections

Acute myeloid leukemia (AML) is a particularly aggressive form of the disease. It starts in the bone marrow, stopping the production of normal blood cells, leading to fatal infections and bleeding.

AML is rare. Around 2,600 Britons are diagnosed a year, and 19,520 Americans – accounting for about one percent of each nation's respective cancer rate.

It is possible that they are rapidly developing and their survival rates are low.

Mainstream treatments for AML for the treatment of myeloid leukemia (AML) is a type of cancer

WHAT IS ACUTE MYELOID LEUKEMIA? of the blood and bone marrow with excess immature white blood cells.

Most cases developed from cells that would turn into white blood cells (other than lymphocytes), but some cases of AML developed in other types of blood-forming cells.

AML it quickly moves into the blood.

AML progresses rapidly, with myeloid cells interfering with the production of normal white blood cells, red blood cells, and platelets.

Treatments include chemotherapy, other drug

American Cancer Society

To uncover the earliest steps in the development of AML, the researchers based on the European Bioinformatics Institute (EBI) Collaborating with the European Forensic Investigation in Cancer and Nutrition (EPIC)

This is one of the largest cohorts in the world, with 521,000 participants recruited across 10 European countries and followed for almost 15 years.

Enrolment into EPIC started in 1992 and they were followed by cancer development with

Some later developed AML and, using their stor

The scientists, including researchers from the Princess Margaret Cancer Center in Canada and the Weizmann Institute in Israel, AML patients

They have compared to blood from AML or other related diseases.

The study focuses on the development of AML risk.

However, the researchers discovered that they were en-route to developing AML had a higher num

Senior author Dr. Moritz Gerstung from the EBI said: "More, specific blood test results have been subtly different from those of the later." 'The generosity of the participants in sharing their data and blood samples' is a new and improved method of genetic modification.

' This genetic

Dr. George Vbadiliou from the Wellcome Sanger Institute and the Wellcome-Cambridge MRC Cambridge Stem Cell Institute said that this is one of the most important causes of cancer. : 'Our study provides for the first time evidence that we can identify people at risk of developing AML many years before they actually develop this life-threatening disease.

' We hope to bui

The Consultant Haematologist at the Cambridge University Hospitals NHS Trust added: 'Our aspirations are that one day AML (19659002) The study was published in the journal Nature.

[ad_2]
Source link